Kymera Therapeutics (KYMR) CEO granted 215,000 stock options at $0 exercise

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported receiving a grant of stock options for 215,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.

According to the disclosure, the options vest in forty-eight equal monthly installments following March 2, 2026, and each portion will vest only if Mainolfi remains employed through the applicable vesting date. All 215,000 stock options are held as direct ownership following this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$90.1	03/02/2026		A		215,000		(1)	03/01/2036	Common Stock	215,000	$0	215,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report for Nello Mainolfi?

Kymera Therapeutics reported that CEO Nello Mainolfi received a grant of stock options for 215,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, indicating a compensatory grant instead of an open-market purchase.

How many Kymera Therapeutics (KYMR) stock options were granted to the CEO?

CEO Nello Mainolfi was granted stock options covering 215,000 shares of Kymera Therapeutics common stock. After this grant, he directly holds options over the same 215,000 shares, as reported in the filing’s post-transaction ownership disclosure.

What is the vesting schedule for Nello Mainolfi’s Kymera Therapeutics stock options?

The stock options granted to Nello Mainolfi vest in 48 equal monthly installments following March 2, 2026. Each monthly tranche vests only if he continues his employment with Kymera Therapeutics through the respective vesting date, aligning the award with ongoing service.

What does a $0.00 exercise price mean for Kymera Therapeutics (KYMR) CEO’s stock options?

The stock options were reported with an exercise price of $0.00 per share, which characterizes the award as a grant or other acquisition under compensation arrangements. It does not represent a market purchase and reflects equity-based compensation terms for the CEO.

Is Nello Mainolfi’s ownership in Kymera Therapeutics from this grant direct or indirect?

The filing states that the 215,000 stock options are held with direct ownership by Nello Mainolfi. There is no indication in the provided footnote of any trust, partnership, or other entity holding the options on his behalf.

How is the Form 4 transaction for Kymera Therapeutics (KYMR) CEO classified?

The transaction is classified as a grant, award, or other acquisition of a derivative security. It is coded as an “A” transaction on the Form 4 and described as a stock option (right to buy) rather than a purchase or sale in the open market.